Panaxadiol is a
triterpenoid sapogenin monomeric compound found in the roots of Panax ginseng and has a variety of
biological activities such as neuroprotective and anti-tumour functions. However, the mechanisms how
panaxadiol exerts the anticancer effects remain unknown. The current study aimed to investigate the potential activity of
panaxadiol on programmed cell death-
ligand 1 (PD-L1) expression and tumour proliferation in human
colon cancer cells and to identify the underlying mechanism. Results showed that
panaxadiol showed little cytotoxicity as assessed by a cytotoxicity assay and significantly inhibited PD-L1 expression at the
protein and
mRNA level in a dose-dependent manner. Furthermore,
panaxadiol supressed the
hypoxia-induced synthesis of
hypoxia-inducible factor (HIF)-1α via the
phosphoinositide 3-kinase (PI3K) and
mitogen-activated protein kinase (MAPK) pathways without affecting HIF-1α degradation. Simultaneously,
panaxadiol inhibited STAT3 activation through the JAK1, JAK2, and Src pathways. Moreover, pre-treatment with
panaxadiol enhanced the activity of cytotoxic T lymphocytes (CTL) and regained their capacity of tumour cell killing in a T cell and tumour cell co-culture system. Immunoprecipitation showed that
panaxadiol inhibited PD-L1 expression by blocking the interaction between HIF-1α and STAT3. The inhibitory effect of
panaxadiol on tumour proliferation was further demonstrated by colony formation and EdU labelling assays. The anti-proliferative effect of
panaxadiol was also proved by a xenograft assay in vivo. Taken together, the current work highlights the anti-tumour effect of
panaxadiol, providing insights into development of
cancer therapeutic through PD-L1 inhibition.